ICON has also appointed Gary Curtis as its new senior vice president of global clinical pharmacology. Dr Curtis will integrate the Omaha facility with ICON’s existing Phase I units and will be supported by key clinical operational staff from Qualia who have been rehired by ICON.
Thomas Frey, president of development solutions at ICON, said: “This latest acquisition supports our strategy of expanding our Phase I capabilities in the US and brings our total bed capacity there to approximately 225 beds. We have acquired an excellent facility and we have put in place an experienced team who will ensure the delivery of quality clinical pharmacology services to clients.”